Objectives. This review summarizes the results of single-photon emission computed tomographic (SPECT) technetium-99m (Tc99m) tracer imaging in patients with stable symptoms, patients with acute coronary syndromes, patients undergoing major noncardiac surgery and patients with chest pain in the emergency department.
The Food and Drug Administration approved the clinical use of technetium-99m (Tc-99m) sestamibi for myocardial perfusion imaging in 1991 and Tc-99m tetrofosmin in 1996 (1) . In 1996, technetium tracers were used in ϳ59% of the 4.9 million studies performed, either alone or in combination with thallium-201 (Tl-201) (dual-isotope imaging) (Technology Marketing Group).
As with thallium, there has been a gradual shift from diagnostic to prognostic applications of technetium tracers. This shift occurred at a time when the prognostic value of stress thallium imaging had been well established in many subsets of patients with coronary artery disease (CAD). For example, patients with normal stress thallium images have been shown to have a benign outcome, with a Ͻ1% hard event rate/year (death or nonfatal myocardial infarction (MI) (1) . Patients with abnormal images, including those with fixed defects, reversible defects, increased lung thallium uptake, left ventricular (LV) dilation, multivessel abnormalities and large perfusion abnormalities, are at higher risk; the risk increases in proportion to the degree of the abnormality (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) .
There are obviously many important differences between Tl-201 and technetium tracers, among which are the lower extraction of the technetium tracers and the ambiguity of the implications of the lung tracer uptake. Nevertheless, several studies, including multicenter studies, showed that the diagnostic accuracy of technetium tracers is comparable to that of Tl-201 (1). This comparability, but not superiority (despite superior imaging characteristics), has been a matter of controversy and has been attributed to many factors, including but not limited to referral bias and observer experience. However, diagnostic accuracy is a moving target, and the recent introduction of gating, which allows simultaneous assessment of perfusion and function as well as the ability to perform attenuation, scatter and depth resolution compensation, has literally made the earlier results obsolete (14, 15) .
It is nevertheless important to examine the prognostic value of technetium-labeled tracers, and because of the longer duration of the use of sestamibi, the latter will be the subject of this review, which includes an analysis of published reports in English in patients with stable symptoms, patients with acute coronary syndromes, patients undergoing major noncardiac surgery and patients with chest pain in the emergency department. All studies were performed with single-photon emission computed tomography (SPECT) but without gating or attenuation correction.
Patients With Stable Chest Pain Syndromes
A summary of the studies dealing with patients with stable chest pain syndromes is presented in Table 1 (16 -29) . The stress modalities included exercise in eight studies and pharmacologic modalities in six. In three studies from the same institution (16, 19, 20) , a dual-isotope protocol (rest thallium and stress sestamibi) was used, but because the prognostic value was related to the stress images, these studies were included here. Four of the 14 studies were from the same institution; 3 of these 4 studies used exercise and 1 pharmacologic testing. It is conceivable that the largest study (20) also included patients described in earlier, smaller studies (16, 23) . Cumulatively, there were Ͼ12,000 patients in these studies; 55% of patients were men, and the mean age of the patients was 61 years. Traditional coronary risk factors were present in many patients, such as remote MI in 22%, hypertension in 50% and diabetes mellitus in 16%. The average follow-up period was 20 months.
The annual rate of hard cardiac events (death or nonfatal MI) in patients with normal stress SPECT sestamibi images and in those with abnormal images is shown in Table 1 . The average annual event rate was 12-fold higher in patients with abnormal images than in patients with normal images (7.4% vs. 0.6%) (Fig. 1) . Therefore, patients with normal stress sestamibi images had a very low hard event rate of Ͻ1%/year, similar to the experience with stress thallium imaging. This event rate is comparable to that in the general population in the United States (30) . In all studies, both fixed and reversible defects were prognostically important. Fixed defects are a more important predictor of death whereas reversible defects are an important predictor of nonfatal MI. Studies that included quantitative assessment of defect size (16, 19, 20, 23) showed that the event rate was significantly greater in patients with severe than in those with mild abnormalities. For example, in one study (16) , the annual hard event rate was 10.6% in patients with severe and 3.5% in patients with mild abnormalities and in another (19) , the annual hard event rate was 6% and 3%, respectively. Furthermore, the prognostic power of normal and abnormal stress images was equally important in men and women. In fact, women with severe abnormalities had a worse outcome than men with severe abnormalities (8% vs. 4% [5] ). Incorporation of other SPECT variables, such as LV dilation (transient or fixed), LV ejection fraction (LVEF) and volumes (derived from gated SPECT), are likely to further enhance the prognostic power of SPECT imaging but require further study (7, 9, 10, 15) .
Classification of patients into low and high risk has been confirmed regardless of the pretest probability of CAD; that is, patients with a high pretest probability of CAD but normal stress SPECT images have a benign outcome, as do patients with a low pretest probability of CAD and normal images. However, because the overall risk in patients with a low pretest probability of CAD is low, stress imaging in this group is probably not cost-effective. The most cost-effective strategy is to study patients with an intermediate to high pretest probability of CAD (19, 20) . Furthermore, when quantitative analysis such as the summed stress score (determined by the extent and severity of abnormalities on the basis of a 20-segment model) was used, the risk of death and nonfatal MI varied according to the severity of abnormalities (19, 31) . For example, patients with mild abnormalities had an intermediate risk of nonfatal MI and a low risk for cardiac death, whereas patients with severe abnormalities had a high risk for death and an intermediate risk for nonfatal MI. These observations are important because coronary revascularization, including percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft surgery (CABG), have not been shown to lower the rate of nonfatal MI (32) .
In our experience (5), events occurred ϳ2 years from the index stress test in patients with normal SPECT images. This finding may suggest that the "warranty" period for a normal stress sestamibi scan (i.e., duration of follow-up after a normal stress study) appears to be ϳ2 years; after that period, the event rate increases, probably reflecting the progressive nature of underlying CAD. However, the value of follow-up periodic testing in asymptomatic patients is still unclear because of improvements in medical therapy.
The prognostic value of stress testing with SPECT has also been confirmed in relation to the Duke treadmill exercise score. This score, which incorporates exercise duration and ST segment depression and angina during exercise, has been used to stratify patients into low, intermediate and high risk groups (33, 34) . The intermediate risk group comprised at least 50% of patients studied in a multicenter study of Ͼ4,581 patients (35) . Patients with an intermediate Duke treadmill exercise score and normal SPECT images (50% of these were done with sestamibi) had an event rate of only 0.2%/year. American College of Cardiology/American Heart Association guidelines reports (36, 37) have recommended that patients with an intermediate Duke score undergo either coronary angiography or an imaging modality (36, 37) . It is to be hoped that subsequent practice guidelines will carefully consider the new evidence and recommend the use of stress myocardial perfusion imaging in such patients.
It is equally important to note that the rate of early catheterization and coronary angiography was very low in patients with normal images (3.8% [16] , 1% [19] and 1.4% [14] ) and appropriately high in patients with abnormal images (17% [19] and 10% [16] for mild abnormalities, 42% [19] and 27% [16] for severe abnormalities).
Noncardiac Surgery
Several guidelines have been published for risk assessment of patients undergoing major noncardiac surgery (38 -41) . This review is not intended to summarize these guidelines nor to critique them, but only to provide summary of published reports on the use of Tc-99m sestamibi. The risk after major noncardiac surgery includes perioperative and late events. The perioperative risk is exceedingly low in patients with normal stress sestamibi images. Similar to that in patients with stable symptoms, the late event rate is significantly higher in patients with abnormal than in those with normal scans (Table 2) (42-44). 
Acute Coronary Syndromes
A limited number of studies in small groups of patients have evaluated the use of sestamibi imaging either at rest or during stress in patients with unstable angina or after acute MI. Again, patients with normal images or small defects have a significantly better outcome than patients with abnormal images or large defects (Table 2 ) (45) (46) (47) (48) (49) . Patients with an acute MI may benefit from simultaneous assessment of myocardial perfusion and function using gated perfusion imaging because both LVEF and perfusion defect size are prognostically important. Preliminary data from a multicenter study of 268 patients demonstrated (50) that early pharmacologic stress imaging may be useful for risk stratification in patients admitted with a diagnosis of acute MI. More studies in larger series of patients with and without thrombolytic therapy and or angioplasty are needed.
Patients With Chest Pain in the Emergency Department
It is estimated that 6 million patients/year visit the emergency department in the United States for evaluation of chest pain (7% of all visits), and although only 10% to 15% of these patients have an acute MI, ϳ50% are admitted to the coronary care unit to rule out acute MI (51) (52) (53) (54) (55) (56) . Several studies show that patients with a low risk rest perfusion scan with Tc-99m sestamibi in the emergency department have a low subsequent cardiac event rate, whereas patients with a high risk scan have a higher probability of acute MI, revascularization or documentation of stenoses on cardiac catheterization (Table 3 ) (56 -60) .
Conclusions
Several studies show that patients with chest pain syndromes but normal stress SPECT perfusion images using Tc-labeled tracers have a very low event rate (Ͻ1%/year for death or nonfatal MI). It is therefore very unlikely that further invasive strategies, including PTCA or CABG, can improve the outcome. These results are similar to those for stress SPECT thallium imaging but differ from stress two-dimensional echocardiography. Multiple studies using stress echocardiography have shown (61) a higher event rate in patients with no evidence of ischemia. The difference between the prognostic value of different stress tests underscores the fact that outcome results by one method cannot be extrapolated to another. The risk of events is substantially higher in patients with abnormal than in those with normal SPECT imaging results. The management of patients with abnormal images as well as the frequency of testing are not clear and should at present be individualized; they deserve further study.
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